Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology
Executive Summary
Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy.
You may also be interested in...
Otsuka Expands Ocular Gene Therapy Interests Through ShapeTX Deal
Otsuka steps into the ocular gene therapy field through a technology licensing deal worth up to $1.5bn with ShapeTX, which in turn further expands the US firm's global reach following a $3bn collaboration with Roche.
Roche Inks Another AAV Capsid Platform Technology Deal, With Avista Therapeutics
Deal Snapshot: Roche and University of Pittsburgh spinout Avista Therapeutics signed the pact to enable the Swiss drug maker to develop gene therapies for retinal diseases using Avista’s platform tech.
Roche Partnering Finds Upfront Fee Relief In Current Market
Barbara Lueckel, head of research technologies partnering, said Roche’s approach to platform deals has evolved with a focus on “generational technologies” to answer tough scientific questions.